BHARAT BIOTECH


Lead Innovation

COVID-19 Vaccine: Clinical Trials and Tribulations

Dr. Raches Ella Project Lead SARS-CoV-2 Vaccines

Types of Vaccines






VERO CELL MANUFACTURING PLATFORM



Developed several inactivated Vero cell derived vaccines which are proven, time-tested and long-lasting. A few include:



BBV 152 : BSL3 PRODUCTION FACILITY



Designed and constructed during 2017 – 2019


Facility audited by ICMR technical team 2019

Designed for large scale manufacturing and testing



COVAXIN™ PROGRESS






BBV152 PRECLINICAL PROFILE



STUDY DESIGN



NON-HUMAN PRIMATES & HAMSTER STUDIES



Preclinical Evaluation of Live Viral Challenge Studies



TWO BBV152 PAPERS (UNDERGOING PEER-REVIEW)

BHAZAI BIOTECH Lead Innovation

ARTICLE General Microbiology Vaccine Development

Remarkable immunogenicity and protective efficacy of BBV152, an inactivated SARS-CoV-2 vaccine in rhesus macaques

Pragya Yadav, Raches Ella, Sanjay Kumar, Dilip Patil, Sreelekshmy Mohandas, Anita Shete, Gaurav Bhati, Gajanan > Sapkal, Himanshu Kaushal, Savita Patil, Railaxmi Jain, Gururaj Rao Deshpande, Nivedita Gupta, Kshitij Agarwal, Mangesh Gokhale, Basavaraj Mathapati, Siddhanath Metkari, Chandrashekhar Mote, Dimpal Nyayanit, Deepak Patil, Sai Prasad B S, Annasaheb Suryawanshi, Manoj Kadam, Abhimanyu Kumar, Sachin Daigude, Sanjay Gopale, Triparna Majumdar, Deepak Mali, Prasad Sarkale, Shreekant Baradkar, Pranita Gawande, Yash Joshi, Sidharam Fulari, Hitesh Dighe, Sharda Sharma, Rashmi Gunjikar, Abhinendra Kumar, Kaumudi Kalele, V K Srinivas, Krishna Mohan, Raman Gangakhedkar, Krishna Ella, Priya Abraham, Samiran Panda, Balram Bhargava

DOI: 10.21203/rs.3.rs-65715/v1 Download PDF

natureresearch



RESEARCH ARTICLE Vaccine Development

Immunogenicity and protective efficacy of BBV152: a whole virion inactivated SARS CoV-2 vaccine in the Syrian hamster model

Sreelekshmy Mohandas, Pragya D Yadav, Anita Shete, Priya Abraham, Krishna Mohan, Gajanan > Sapkal, Chandrashekhar Mote, Dimpal Nyayanit, Nivedita Gupta, V K Srinivas, Manoj Kadam, Abhimanyu Kumar, Rajlaxmi Jain, Triparna Majumdar, Gururaj Deshpande, Savita Patil, Prasad Sarkale, Deepak Patil, Raches Ella, Sai D Prasad, Sharda Sharma, Krishna M Ella, Samiran Panda, **Balram Bhargava**


DOI: 10.21203/rs.3.rs-76768/v1 Download PDF



1. NON-HUMAN PRIMATE – STUDY DESIGN




- □ A 2-dose vaccination regimen of inactivated SARS-CoV-2 vaccine candidates was administered in 20 rhesus macaques (divided into four groups equally).
- One group was administered with placebo while three groups were immunized with 3 different vaccine candidates at 0 and 14 days. All the macaques were exposed to viral challenge 14 days after the 2nd dose.



LOAD OF COVID-19 SUBGENOMIC VIRAL RNA DETECTION IN RESPIRATORY TRACT SPECIMENS






2. HAMSTER CHALLENGE - STUDY DESIGN




- Thirty-six female Syrian hamsters were divided into four groups of 9 hamsters each. Each group were immunized with 0.1 ml of PBS/vaccine formulations intramuscularly on 0, 14, and 35 days.
- □ The immunized hamsters were challenged with 0.1 ml of 105.5 TCID50 SARS-CoV-2 virus intranasally on the 8th-week post-immunization (day 50).



LOAD OF COVID-19 SUBGENOMIC VIRAL RNA DETECTION IN RESPIRATORY TRACT SPECIMENS





STATUS UPDATE & MILESTONES



PHASE I

IM study:

- Administered at 14 day interval
- □ 375 subjects.

ID study:

Administered in 24 subjects.

Status: Completed

PHASE II

IM study:

- Administered at a 28day interval.
- Includes 380 subjects.
- Dose-1 has been administered.

ID study:

Administered in 100 subjects.

Status: Initiated

PHASE III

- Scheduled to commence in October all over India around 25 centers
- Trial includes >25,000 subjects
- IM study with 2-dose vaccine regimen administered at a 28day interval.
- Status: To initiate


WHOLE-VIRION INACTIVATED SARS-CoV-2 VACCINE (BBV152) IN HEALTHY VOLUNTEERS - A PHASE 1 STUDY



Phase 1 trial overview (NCT04471519)							
Protocol Title	Phase 1, double blind, multi-centre study of safety, reactogenicity, tolerability, and immunogenicity in 375 healthy volunteers.						
Study Groups	Cohorts/ Vaccine Candidates	Age groups	Dosage (D0, D14)	Enrollment status			
	BBV152A	≥18 to ≤55	0.5 mL of Whole Virion Inactivated SARS-CoV-2 Vaccine	(Fully enrolled) 100			
	BBV152B	years		(Fully enrolled) 100			
	BBV152C			(Fully enrolled) 100			
	Placebo		0.5 mL placebo	(Fully enrolled) 75			
Population	Participants of either gender of age between ≥18 to ≤55 years.						
Study Endpoints	Safety (Mild AEs were noted within 2 hours after Dose 1. No immediate AEs were reported after Dose 2). Immunogenicity (e.g., neutralizing antibody titers are suggestive of protection)						
Study Duration	12-month follow up study after the last vaccine administration.						

PHASE 1 & 2: GEOGRAPHIC SPREAD





List of Hospitals Across India					
All India Institute of Medical Sciences, Delhi					
Rana Hospital and Trauma Center, Gorakhpur					
All India Institute of Medical Sciences, Patna					
Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak					
Prakhar Hospital, Kanpur					
Gillukar Multispeciality Hospital, Nagpur					
Redkhar Hospital, Dhargalim VP					
Jeevan Rekha Hospital, Belgaum					
Institute of Medical Sciences and SUM Hospital, Bhubaneshwar					
Nizam Institute of Medical Sciences Hospital, Hyderabad					
SRM Hospital & Research Center, Chennai					

A PHASE 2 STUDY SHOWING WHOLE-VIRION INACTIVATED SARS-CoV-2 VACCINE (BBV152) IN HEALTHY VOLUNTEERS



Phase 2 trial ove	rview (NCT044715	19)					
Protocol Title	Phase 2, double blind, multi-centre study of safety, reactogenicity, tolerability, and immunogenicity in 380 healthy volunteers.						
Study Groups	Cohorts/ Vaccine Candidates	Age groups	Dosage (D0, D28)	Enrollment status			
	BBV152A	≥12 to ≤65 years	0.5 mL	(Fully enrolled) 190			
	BBV152B		0.5 mL	(Fully enrolled) 190			
Population	Participants of either gender of age between ≥12 to ≤65 years.						
Study Endpoints	No immediate AEs occurred within 2 hrs after vaccination; there were no SAEs reported. Immunogenicity (e.g., neutralizing antibody titers are suggestive of protection)						
Study Duration	6-month study after the last vaccine administration.						

BHARAT BIOTECH Lead Innovation

Phase 3 Efficacy Trial (n=26,000)



Home >News >India >Covaxin update: Bharat Biotech gets nod from DCGI panel for Phase III trials



The human trials of Covaxin has begun at the All India Institute of Medical Sciences

Covaxin update: Bharat Biotech gets nod from DCGI panel for Phase III trials

